Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS. Braciak TA, et al. Among authors: subklewe m. Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018. Oncoimmunology. 2018. PMID: 30228941 Free PMC article.
[Hematology 2010].
Dreyling M, Subklewe M, Braess J, Spiekermann K. Dreyling M, et al. Among authors: subklewe m. Dtsch Med Wochenschr. 2010 Jun;135(25-26):1322-5. doi: 10.1055/s-0030-1255163. Epub 2010 Jun 16. Dtsch Med Wochenschr. 2010. PMID: 20556691 Review. German. No abstract available.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M. Krupka C, et al. Among authors: subklewe m. Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3. Blood. 2014. PMID: 24300852 Free article.
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H. Janke H, et al. Among authors: subklewe m. PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. eCollection 2014. PLoS One. 2014. PMID: 24608088 Free PMC article.
Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.
Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A. Witter K, et al. Among authors: subklewe m. Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. Epub 2014 Apr 3. Bone Marrow Res. 2014. PMID: 24860670 Free PMC article.
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I. Vick B, et al. Among authors: subklewe m. PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. eCollection 2015. PLoS One. 2015. PMID: 25793878 Free PMC article.
Immunotherapy for Acute Myeloid Leukemia.
Lichtenegger FS, Krupka C, Köhnke T, Subklewe M. Lichtenegger FS, et al. Among authors: subklewe m. Semin Hematol. 2015 Jul;52(3):207-14. doi: 10.1053/j.seminhematol.2015.03.006. Epub 2015 Mar 17. Semin Hematol. 2015. PMID: 26111468 Review.
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M. Krupka C, et al. Among authors: subklewe m. Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4. Leukemia. 2016. PMID: 26239198
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M. Lichtenegger FS, et al. Among authors: subklewe m. Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8. Epub 2015 Sep 16. Cancer Immunol Immunother. 2015. PMID: 26377688 Free PMC article.
200 results